Alnylam licenses RNAi cholesterol drugs to Medicines Company

02/4/2013 | Genetic Engineering & Biotechnology News

Alnylam Pharmaceuticals granted the Medicines Company the right to develop and market a series of RNA interference-based, cholesterol-lowering drug candidates. The deal covers ALN-PCS02, an experimental intravenous RNAi treatment, and ALN-PCSsc, a preclinical injectable RNAi candidate. Alnylam will get $25 million immediately and as much as $180 million in potential milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
Nationwide, SL_Nationwide
Finance Manager - ENT
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA